JP7108320B2 - 片頭痛の症状を管理するためのグリセリル３－ヒドロキシブチラート - Google Patents
片頭痛の症状を管理するためのグリセリル３－ヒドロキシブチラート Download PDFInfo
- Publication number
- JP7108320B2 JP7108320B2 JP2019534701A JP2019534701A JP7108320B2 JP 7108320 B2 JP7108320 B2 JP 7108320B2 JP 2019534701 A JP2019534701 A JP 2019534701A JP 2019534701 A JP2019534701 A JP 2019534701A JP 7108320 B2 JP7108320 B2 JP 7108320B2
- Authority
- JP
- Japan
- Prior art keywords
- hydroxybutyrate
- glyceryl
- subject
- compound
- migraine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000019695 Migraine disease Diseases 0.000 title claims description 108
- 206010027599 migraine Diseases 0.000 title claims description 85
- 208000024891 symptom Diseases 0.000 title claims description 47
- CBTHKODKAPVTNY-UHFFFAOYSA-N 2,3-dihydroxypropyl 3-hydroxybutanoate Chemical compound CC(O)CC(=O)OCC(O)CO CBTHKODKAPVTNY-UHFFFAOYSA-N 0.000 title claims description 8
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical group CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims description 46
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 claims description 37
- -1 glyceryl (3-hydroxybutyrate) ester Chemical class 0.000 claims description 32
- 239000007983 Tris buffer Substances 0.000 claims description 30
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 25
- 230000001667 episodic effect Effects 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 20
- 206010027603 Migraine headaches Diseases 0.000 claims description 19
- 150000002576 ketones Chemical class 0.000 claims description 19
- 150000002148 esters Chemical class 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 206010019233 Headaches Diseases 0.000 claims description 16
- 231100000869 headache Toxicity 0.000 claims description 16
- 230000001684 chronic effect Effects 0.000 claims description 14
- 230000036470 plasma concentration Effects 0.000 claims description 14
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 208000037048 Prodromal Symptoms Diseases 0.000 claims description 5
- 238000011161 development Methods 0.000 claims description 3
- 230000000116 mitigating effect Effects 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims 5
- 238000006460 hydrolysis reaction Methods 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical group CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- WHBMMWSBFZVSSR-GSVOUGTGSA-M (R)-3-hydroxybutyrate Chemical compound C[C@@H](O)CC([O-])=O WHBMMWSBFZVSSR-GSVOUGTGSA-M 0.000 claims 1
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical group CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 claims 1
- 238000012935 Averaging Methods 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 235000020887 ketogenic diet Nutrition 0.000 description 20
- 238000000034 method Methods 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229960003133 ergot alkaloid Drugs 0.000 description 6
- 150000004667 medium chain fatty acids Chemical class 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 5
- 238000002483 medication Methods 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 230000036765 blood level Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000037213 diet Effects 0.000 description 3
- 230000035861 hyperketonemia Effects 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 229940057917 medium chain triglycerides Drugs 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- NHEUWFPWBFBDRF-UHFFFAOYSA-N 2,3-bis(3-hydroxybutanoyloxy)propyl 3-hydroxybutanoate Chemical compound CC(O)CC(=O)OCC(OC(=O)CC(C)O)COC(=O)CC(C)O NHEUWFPWBFBDRF-UHFFFAOYSA-N 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 208000007976 Ketosis Diseases 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical group CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 235000021085 polyunsaturated fats Nutrition 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- 206010000410 Acetonaemia Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- AOWPVIWVMWUSBD-RNFRBKRXSA-N [(3r)-3-hydroxybutyl] (3r)-3-hydroxybutanoate Chemical compound C[C@@H](O)CCOC(=O)C[C@@H](C)O AOWPVIWVMWUSBD-RNFRBKRXSA-N 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000007963 carbohydrate restriction Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000007585 cortical function Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 235000021084 monounsaturated fats Nutrition 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/389,828 | 2016-12-23 | ||
| US15/389,828 US20180177753A1 (en) | 2016-12-23 | 2016-12-23 | Glyceryl 3-hydroxybutyrates for migraine symptom management |
| PCT/US2017/063832 WO2018118369A1 (en) | 2016-12-23 | 2017-11-30 | Glyceryl 3-hydroxybutyrates for migraine symptom management |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502250A JP2020502250A (ja) | 2020-01-23 |
| JP2020502250A5 JP2020502250A5 (enExample) | 2021-01-14 |
| JP7108320B2 true JP7108320B2 (ja) | 2022-07-28 |
Family
ID=62624821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019534701A Active JP7108320B2 (ja) | 2016-12-23 | 2017-11-30 | 片頭痛の症状を管理するためのグリセリル３－ヒドロキシブチラート |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20180177753A1 (enExample) |
| EP (1) | EP3558458B1 (enExample) |
| JP (1) | JP7108320B2 (enExample) |
| KR (1) | KR102390608B1 (enExample) |
| CN (1) | CN110167637B (enExample) |
| BR (1) | BR112019012431A2 (enExample) |
| CA (1) | CA3046350C (enExample) |
| ES (1) | ES2962879T3 (enExample) |
| IL (1) | IL267540B (enExample) |
| MX (1) | MX389468B (enExample) |
| MY (1) | MY190308A (enExample) |
| PT (1) | PT3558458T (enExample) |
| WO (1) | WO2018118369A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
| US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
| US12109182B2 (en) | 2016-04-19 | 2024-10-08 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| US12599579B2 (en) | 2016-04-19 | 2026-04-14 | Axcess Global Sciences, Llc | Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids |
| US12622889B2 (en) | 2016-04-19 | 2026-05-12 | Axcess Global Sciences, Llc | S-β-hydroxybutyrate esters for improving metabolic function |
| US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
| US12533346B2 (en) | 2016-04-19 | 2026-01-27 | Axcess Global Sciences, Llc | Administration of berberine metabolites |
| US12496283B2 (en) | 2016-04-19 | 2025-12-16 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
| US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
| US12521378B2 (en) | 2016-04-19 | 2026-01-13 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans |
| US12329734B2 (en) | 2017-12-19 | 2025-06-17 | Axcess Global Sciences, Llc | Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow |
| US20230346721A1 (en) | 2018-04-18 | 2023-11-02 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies |
| CA3046415A1 (en) | 2016-12-21 | 2018-06-28 | Universitats-Kinderspital Beider Basel | Migraine prevention and treatment |
| US10376528B2 (en) | 2017-03-10 | 2019-08-13 | Tecton Group, Llc | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor |
| GB201715654D0 (en) | 2017-09-27 | 2017-11-08 | Tdeltas Ltd | Method of treatment |
| US12090129B2 (en) | 2017-11-22 | 2024-09-17 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| CN113454055B (zh) * | 2019-01-17 | 2024-07-05 | 凯托利皮克斯治疗有限责任公司 | 生产包含基于羟基羧酸的甘油酯的结构单元的脂质的方法 |
| JP7235873B2 (ja) | 2019-01-17 | 2023-03-08 | アイオーアイ オレオ ゲーエムベーハー | ヒドロキシカルボン酸のグリセリドの製造方法 |
| EP3937656B1 (en) * | 2019-03-14 | 2025-04-02 | Neuroenergy Ventures, Inc. | Taste-masking formulation for ketone body compounds |
| US12472200B2 (en) | 2019-05-15 | 2025-11-18 | Axcess Global Sciences, Llc | Autobiotic compositions and method for promoting healthy gut microbiome |
| KR20220016145A (ko) | 2019-05-30 | 2022-02-08 | 뉴로에너지 벤처스 인코포레이티드 | 글리세릴 트리스(베타-하이드록시부티레이트) 및 신경 일과성 허혈 발작 |
| WO2020249198A1 (de) * | 2019-06-12 | 2020-12-17 | Ioi Oleo Gmbh | Verfahren zur herstellung von polyolbasierten estern von acylverkappten 3-hydroxycarbonsäuren |
| US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
| US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US12167993B2 (en) | 2019-06-21 | 2024-12-17 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| IT201900018491A1 (it) * | 2019-10-10 | 2021-04-10 | Dr Schaer S P A | Procedimento di purificazione del tris-(3-idrossibutirrato)-gliceril estere |
| IT201900018488A1 (it) * | 2019-10-10 | 2021-04-10 | Dr Schaer S P A | Procedimento di preparazione del tris-(3-idrossibutirrato)-gliceril estere |
| US12186297B2 (en) | 2020-08-26 | 2025-01-07 | Axcess Global Sciences, Llc | Compositions and methods for increasing lean-to-fat mass ratio |
| EP4405324A1 (en) | 2021-11-12 | 2024-07-31 | Arxada AG | Polyol-derived compounds |
| US20250002446A1 (en) * | 2021-11-26 | 2025-01-02 | Arxada Ag | Acetoacetate Based Ketals |
| US12622967B2 (en) * | 2022-01-18 | 2026-05-12 | Today, Inc. | Molecules, formulations, and methods for nutritional support of athletes, patients, and others |
| US12023382B2 (en) | 2022-01-18 | 2024-07-02 | Today Inc. | Molecules, formulations, and methods for nutritional support of athletes, patients, and others |
| EP4605371A1 (en) | 2022-10-18 | 2025-08-27 | Arxada AG | Polyol-derived compounds |
| WO2025074001A2 (en) | 2023-10-05 | 2025-04-10 | Arxada Ag | Enzymatic reduction of acetoacetate |
| WO2025196156A1 (en) | 2024-03-20 | 2025-09-25 | Arxada Ag | Continuous hydrogenation process of acetoacetate esters |
| WO2025224319A1 (en) | 2024-04-25 | 2025-10-30 | Arxada Ag | Reduction of acetoacetate esters in the presence of amines |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008005818A1 (en) | 2006-06-30 | 2008-01-10 | Stepan Co | Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose |
| US20080058416A1 (en) | 2004-05-12 | 2008-03-06 | David Greenwood | Cns Modulators |
| US20150065571A1 (en) | 2013-08-07 | 2015-03-05 | Tdeltas Limited | Ketone body and ketone body ester for reducing muscle breakdown |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2500017T (pt) | 2006-04-03 | 2017-11-14 | Accera Inc | Utilização de compostos cetogénicos para tratamento de comprometimento da memória associado à idade |
| CA2750510A1 (en) * | 2009-01-24 | 2010-07-29 | Phytopharm Plc | Treatment of neurotrophic factor mediated disorders |
| WO2012154837A2 (en) | 2011-05-09 | 2012-11-15 | University Of South Florida | The use of ketone esters for prevention of cns oxygen toxicity |
| US20140072654A1 (en) | 2011-12-23 | 2014-03-13 | Savind, Inc. | Cancer with metabolic therapy and hyperbaric oxygen |
| FR2997302B1 (fr) * | 2012-10-29 | 2015-02-06 | Assist Publ Hopitaux De Paris | Prevention et traitement des deficits en pyruvate deshydrogenase |
| JP6883384B2 (ja) | 2012-11-05 | 2021-06-09 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 電離放射線による傷害から組織を防護するためのケトン体 |
| EP2925308B1 (en) | 2012-11-28 | 2019-12-25 | University Of South Florida | Targeting cancer with metabolic therapy and hyperbaric oxygen |
| MY180761A (en) | 2013-03-19 | 2020-12-08 | Univ South Florida | Compositions and methods for producing elevated and sustained ketosis |
| WO2015156865A1 (en) | 2014-01-13 | 2015-10-15 | University Of South Florida | Methods of sustaining dietary ketosis and its effects on lipid profile |
| US20160078782A1 (en) * | 2014-09-17 | 2016-03-17 | The Trustees Of Boston College | Glucose Ketone Index for MetabolicTherapy |
| US9364456B1 (en) | 2015-06-30 | 2016-06-14 | University Of South Florida | Ketone esters for treatment of angelman syndrome |
| US20180200220A1 (en) | 2015-07-10 | 2018-07-19 | Cognate Nutritionals, Inc. | Prophylaxis and mitigation of migraine headaches using ketogenic medium chain triglycerides, ketone esters, and other ketogenic sources |
| US10292952B2 (en) | 2016-03-11 | 2019-05-21 | Axcess Global Sciences, Llc | Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis |
| US10376482B2 (en) | 2016-04-03 | 2019-08-13 | Franco Cavaleri | Butyrate and beta-hydroxybutyrate compositions |
| SG11201809211QA (en) | 2016-04-19 | 2018-11-29 | Keto Patent Group Inc | Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans |
| WO2018009208A1 (en) | 2016-07-08 | 2018-01-11 | Cognate Nutritionals, Inc. | Nutritional mitiggation of the cns effects of traumatic brain injury |
| JP2019526607A (ja) | 2016-09-12 | 2019-09-19 | ユニバーシティ・オブ・サウス・フロリダ | ケトンにより改善された神経再生 |
| CA3046415A1 (en) | 2016-12-21 | 2018-06-28 | Universitats-Kinderspital Beider Basel | Migraine prevention and treatment |
-
2016
- 2016-12-23 US US15/389,828 patent/US20180177753A1/en not_active Abandoned
-
2017
- 2017-11-30 IL IL267540A patent/IL267540B/en unknown
- 2017-11-30 CN CN201780078046.7A patent/CN110167637B/zh active Active
- 2017-11-30 BR BR112019012431A patent/BR112019012431A2/pt not_active Application Discontinuation
- 2017-11-30 PT PT178847570T patent/PT3558458T/pt unknown
- 2017-11-30 WO PCT/US2017/063832 patent/WO2018118369A1/en not_active Ceased
- 2017-11-30 KR KR1020197020923A patent/KR102390608B1/ko active Active
- 2017-11-30 ES ES17884757T patent/ES2962879T3/es active Active
- 2017-11-30 JP JP2019534701A patent/JP7108320B2/ja active Active
- 2017-11-30 CA CA3046350A patent/CA3046350C/en active Active
- 2017-11-30 EP EP17884757.0A patent/EP3558458B1/en active Active
- 2017-11-30 MY MYPI2019003609A patent/MY190308A/en unknown
- 2017-11-30 MX MX2019006844A patent/MX389468B/es unknown
-
2018
- 2018-12-14 US US16/220,365 patent/US10792269B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080058416A1 (en) | 2004-05-12 | 2008-03-06 | David Greenwood | Cns Modulators |
| WO2008005818A1 (en) | 2006-06-30 | 2008-01-10 | Stepan Co | Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose |
| US20150065571A1 (en) | 2013-08-07 | 2015-03-05 | Tdeltas Limited | Ketone body and ketone body ester for reducing muscle breakdown |
Non-Patent Citations (5)
| Title |
|---|
| HASHIM, Sami A. and VANITALLIE, Theodore B.，Ketone body therapy: from the ketogenic diet to the oral administration of ketone ester，Journal of Lipid Research，2014年，Vo. 55，pp. 1818-1826 |
| KOSSOFF, Eric C. and HARTMAN, Adam L.，Ketogenic Diets: New Advances for Metabolism-Based Therapies，Current Opinion in Neurology，2012年，Vo. 25, No. 2，pp. 173-178 |
| LORENZO, C. Di et al.，Migraine improvement during short lasting ketogenesis: a proof-of-concept study，European Journal of Neurology，2014年，Vol. 22, No. 1，pp. 170-177 |
| LORENZO, Cherubino Di et al.，Diet transiently improves migraine in two twin sisters: possible role of ketogenesis?，Functional Neurology，2013年，Vol. 28, No. 4，pp. 305-308 |
| MCCLEARY, Larry，Migraine Headaches - Rethinking an Old Maladay，https://www.brainblogger.com/2008/01/28/rethinking-an-old-malady/ Brain Blogger 2008/01/28，2008年，pp. 1-2 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3558458A4 (en) | 2020-08-12 |
| US20180177753A1 (en) | 2018-06-28 |
| CN110167637B (zh) | 2023-03-14 |
| KR20190099465A (ko) | 2019-08-27 |
| IL267540A (en) | 2019-08-29 |
| CA3046350A1 (en) | 2018-06-28 |
| WO2018118369A1 (en) | 2018-06-28 |
| US20190117612A1 (en) | 2019-04-25 |
| ES2962879T3 (es) | 2024-03-21 |
| CA3046350C (en) | 2022-08-16 |
| MY190308A (en) | 2022-04-13 |
| MX389468B (es) | 2025-03-20 |
| JP2020502250A (ja) | 2020-01-23 |
| EP3558458B1 (en) | 2023-10-18 |
| IL267540B (en) | 2022-07-01 |
| MX2019006844A (es) | 2019-08-16 |
| US10792269B2 (en) | 2020-10-06 |
| PT3558458T (pt) | 2023-11-27 |
| KR102390608B1 (ko) | 2022-04-25 |
| BR112019012431A2 (pt) | 2020-04-14 |
| CN110167637A (zh) | 2019-08-23 |
| EP3558458A1 (en) | 2019-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110167637B (zh) | 3-羟基丁酸甘油酯用于偏头痛症状管理 | |
| JP7278593B2 (ja) | 外傷性脳損傷のためのグリセリル３－ヒドロキシブチラート | |
| DK2691086T3 (en) | COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | |
| CN101765427A (zh) | 在简易精神状态检查值为24-26的受试者中改善记忆 | |
| JPH02104522A (ja) | 脂肪酸を含有する医薬用組成物 | |
| JP2017519028A (ja) | 重度の高トリグリセリド血症の処置 | |
| CN116490181A (zh) | 在人中施用β-羟基丁酸和相关化合物用于治疗和/或预防呼吸道疾病 | |
| HK40012930B (en) | Glyceryl 3-hydroxybutyrates for migraine symptom management | |
| US20240382445A1 (en) | Methods of adjuvant therapy | |
| US7208522B1 (en) | Methods and compositions for the prevention and treatment of Syndrome X | |
| Kłęk et al. | The use of intravenous emulsions containing omega-3 unsaturated fatty acids in clinical practice: recommendations of a team of experts | |
| HK40012930A (en) | Glyceryl 3-hydroxybutyrates for migraine symptom management | |
| HK40012461A (en) | Glyceryl 3-hydroxybutyrates for traumatic brain injury | |
| WO2002009692A1 (en) | Methods and compositions for the attenuation and/or prevention of stress/catabolic responses | |
| Furman et al. | Workshop: Dietary Management of Hyperlipoproteinemias | |
| NZ616554B2 (en) | Compositions for the treatment of neurologic disorders | |
| HK1194665B (en) | Compositions for the treatment of neurologic disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A525 Effective date: 20190704 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201120 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201120 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210823 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210831 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220420 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220601 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220628 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220708 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7108320 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |